ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer Post author:admERY Post published:September 26, 2016 Post category:Newsroom ERYTECH Pharma today announced the final patient has been enrolled in its Phase 2 trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of pancreatic cancer. You Might Also Like ERYTECH to Participate in Upcoming Virtual Investor Conferences in June May 26, 2021 ERYTECH Provides Business Update and Reports Financial Results for Full Year 2018 March 11, 2019 ERYTECH to present at upcoming investor conferences May 20, 2013